GLP-1 & incretin peptides

GLP-1 blind panel

Targeted blind identification and measurement within a defined semaglutide, tirzepatide, and retatrutide panel.

Detected identity mg/vial or stated basis Area % where interpretable

Back to Peptides

Choose the sample form and any compatible add-ons below.

Base analysis

Included in this analytical scope

Defined three-analyte identity panel

Amount for resolved detected targets

Method-defined chromatographic profile

Sample form

Submission type

Optional measurements

Add compatible analyses.

Selections create a scope request, not a confirmed order. Compatibility and reporting basis are reviewed before sample shipment.

LC-MSLC-MS identity confirmationOrthogonal mass-spectral support for the declared molecular identity.CHNS / compositional modelNet peptide contentA separate compositional result that is not the same as HPLC area purity.LALBacterial endotoxinLAL measurement under stated conditions and on a defined reporting basis.TAMC / TYMCMicrobial enumerationTAMC and TYMC recovery under stated conditions; this is not a sterility test.Elemental screenElemental screeningSelected elemental signals within the agreed method and reporting capability.DocumentationRaw-data packageAvailable chromatograms, spectra, and method-defined acquisition records supplied with the report.DocumentationAdditional issued reportA separately issued copy or reporting variant defined during scope review.

GLP-1 blind panel

0 optional analyses selected

Analytical boundary: Blind means the declared identity is not relied upon. It does not mean unrestricted discovery of every possible unknown, and mixture purity is reported only when analytically interpretable.

Need a different target?

Return to the full peptides catalog.

Browse all tests